TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a 31-patient phase II trial, brepocitinib was associated with substantially lower cutaneous sarcoidosis activity scores after 16 weeks than placebo. The results are promising but preliminary; a phase III trial is underway, with primary results expected at the end of 2028.
A 31-patient phase II trial found that brepocitinib, a TYK2/JAK1 inhibitor, reduced measures of skin disease activity in people with cutaneous sarcoidosis over 16 weeks, while scores did not decline in the placebo group. The findings, reported by Misha Rosenbach of the University of Pennsylvania and colleagues, offer early evidence for a potential treatment for a condition with limited effective options; they do not establish that the drug is effective or approved for sarcoidosis.
Participants were randomly assigned to take 45 mg or 15 mg of brepocitinib daily or placebo. The primary measure was change in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score. After 16 weeks, both brepocitinib groups had an average reduction of about 22 points, exceeding the study’s five-point threshold for clinical relevance. The placebo group showed no reduction, according to the trial report.
Some outcomes differed by dose. A reduction of at least 10 CSAMI-A points occurred in all participants in the 45-mg group, 73% of those taking 15 mg and 14% of those on placebo. Functional remission, defined in the study as a score below 5, was reached by 62% on the higher dose, 46% on the lower dose and none on placebo. All five participants taking 45 mg who had lupus pernio, a form of facial and cranial lesions, had reductions of at least 10 points.
The researchers also reported improvement in skin-related quality of life among participants receiving brepocitinib. No serious adverse events were recorded. One participant in each study group stopped treatment because of an adverse event. The report noted a creatine kinase elevation and an anemia case in the 45-mg group, and did not report other specified events of special interest during the trial.
A Potential Option for Difficult Skin Disease
Cutaneous sarcoidosis can cause persistent skin lesions, including lupus pernio, and current treatments do not work reliably for everyone. The report says corticosteroids, a longstanding mainstay, may have inconsistent effects and relapses are common among people who respond. Other commonly used treatments, including hydroxychloroquine and methotrexate, also have limitations.
The size of the reported score changes and the gap between treatment and placebo groups make brepocitinib a candidate for further study. They may matter to patients who have not had adequate results with existing options. But this was a small, 16-week phase II trial; the findings cannot establish how the medicine would perform across a broader population, how durable any benefit would be, or where it should fit among treatments.
Products Worth Considering
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
Garmin Forerunner 935 GPS Running and Multisport Watch, Black
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
As an affiliate, we earn on qualifying purchases.
Earlier Evidence and the Trial Design
Clinicians have explored Janus kinase inhibitors as alternatives for cutaneous sarcoidosis, but earlier reports on medicines such as tofacitinib and upadacitinib were limited to individual cases and small case series. A report of deucravacitinib also described a positive result in one patient. Those reports are not comparable to a randomized trial, but they help explain the interest in studying drugs that affect related immune pathways.
Brepocitinib was approved by the U.S. Food and Drug Administration in August 2026 for dermatomyositis, according to the source report; that approval is separate from its investigational use for sarcoidosis. In this phase II study, 31 patients were assigned in a 3:2:2 ratio to the 45-mg dose, 15-mg dose or placebo. Participants could continue conventional non-targeted treatments. Oral steroids were withdrawn during the first eight weeks, and topical steroids were stopped when participants entered the study.
The trial’s participants generally were in their 40s and 50s, and baseline CSAMI-A scores averaged about 34. Disease duration differed across groups: approximately 10 years in the placebo and higher-dose groups and four years in the lower-dose group. Pulmonary sarcoidosis was common among participants, but the study’s main focus was skin outcomes.
“I imagine many patients would get it as first line.”
— Misha Rosenbach, University of Pennsylvania
Questions Beyond the Skin Scores
The phase II results do not show whether the improvements will persist after 16 weeks or how the medicine will compare with existing treatments in larger, more varied groups. The study also cannot settle the drug’s longer-term safety profile. Although it recorded no serious adverse events, 31 participants are too few to rule out uncommon or delayed harms.
Effects on pulmonary and joint symptoms remain uncertain. Rosenbach said the studies to date had focused on skin and that other symptoms would almost certainly be examined in phase III. The report does not provide phase III enrollment details or a projected completion date beyond the expected timing of primary results.
Phase III Results Expected in 2028
A larger phase III trial is underway, with the 45-mg dose selected for testing for potential sarcoidosis approval. Priovant Therapeutics expects primary results at the end of 2028, according to the report. Those results should provide stronger evidence about efficacy and safety than the small phase II study, and may help clarify the drug’s place in treatment.
Until then, brepocitinib’s phase II findings remain preliminary and do not amount to an approval for cutaneous sarcoidosis. The larger study is also expected to examine symptoms beyond the skin, including pulmonary and joint manifestations, though the source report does not give specific outcome measures or further trial details.
Key Questions
What did the brepocitinib trial find?
In a 31-person phase II trial, both tested doses were associated with an average 22-point reduction in skin activity scores after 16 weeks. The placebo group had no average reduction, according to the report.
Is brepocitinib approved for cutaneous sarcoidosis?
The results do not indicate approval for sarcoidosis. The source report says brepocitinib was approved for dermatomyositis; its use for cutaneous sarcoidosis is being studied in a phase III trial.
Were serious side effects reported?
The phase II report recorded no serious adverse events. One participant in each study group stopped treatment because of an adverse event. The trial was small and short, so it cannot rule out uncommon or longer-term risks.
Could the drug help lung or joint symptoms?
The available studies focused mainly on skin outcomes. Rosenbach said the effects on pulmonary and joint manifestations were not yet clear and would likely be examined in the phase III trial.
When are larger-trial results expected?
Priovant Therapeutics expects primary results from the phase III study at the end of 2028, according to the report.
Source: medpagetoday.com
